NEWS HIGHLIGHTSMedia Articles Related to Emcyt (Estramustine)
Tulane Cancer Center To Begin Novel Clinical Trial For Late-Stage Prostate Cancer Drug
Source: Prostate / Prostate Cancer News From Medical News Today [2009.11.18]
International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide.
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone (HE3235) At AACR Molecular Targets Conference
Source: Conferences News From Medical News Today [2009.11.17]
Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC).
Anxiety And Distress During Active Surveillance For Early Prostate Cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2009.11.16]
UroToday.com - The present study found that the majority of men with early prostate cancer (PC) included in a protocol-based program for active surveillance (AS) show favorable anxiety and distress scores when compared to reference values and to groups of patients with PC who underwent other treatments.
Percentage Of Positive Biopsy Cores At The Onset Of Hormone Therapy For Prostate Cancer: Prognostic Significance
Source: Prostate / Prostate Cancer News From Medical News Today [2009.11.16]
UroToday.com - Accurate prediction of outcome after hormonal treatment for localized prostate cancer is important for patient counselling, follow-up, treatment planning and research protocol design. Few prognostic tools incorporating pre-therapeutic parameters are available to increase disease relapse predictions and survival.
Degarelix: A New Approach For The Treatment Of Prostate Cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2009.11.16]
UroToday.com - Gonadotrophin-releasing hormone (GnRH) agonists are currently the 'standard of care' for androgen deprivation therapy (ADT) in prostate cancer. Improvements in ADT would have a great value for many patients. The agonists are associated with an initial testosterone surge, which delays castration and may stimulate tumor growth and induce 'clinical flare' in patients with symptomatic advanced disease.
Published Studies Related to Emcyt (Estramustine)
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. [2009.03.01]
CONCLUSION: TEE was associated with significantly increased toxicity during treatment. The toxicity profiles did not differ at 2 and 3 years after therapy. Toxicity is an important consideration in the design of trials using adjuvant chemotherapy for prostate cancer.
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. [2008.11.10]
PURPOSE: To assess the efficacy and toxicity of the addition of estramustine to docetaxel (D) for the treatment of metastatic hormone-refractory prostate cancer... CONCLUSION: The addition of estramustine to weekly D does not provide any clinically relevant advantage. Both regimens are well tolerated, although the toxicity profile favors D without estramustine.
Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. [2008.11]
OBJECTIVE: To report the results of a randomized phase II trial of docetaxel with and without estramustine phosphate (EP) in patients with hormone-refractory prostate cancer (HRPC)... CONCLUSION: These data support the existence of a possible advantage in combining docetaxel and EP, which should be verified in a specific randomized phase III study.
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. [2006.10.15]
CONCLUSIONS: DV and DE doublets are active with a tolerable toxicity profile in patients with HRPC; however, efficacy does not seem superior to standard single-agent docetaxel. The ABCG2 421 C > A (Q141K) polymorphism may be an important predictor of response and survival in HRPC patients treated with docetaxel-based chemotherapy.
A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. [2006.09]
OBJECTIVE: To test the combination of docetaxel with two different doses of estramustine in patients with hormone-refractory prostate cancer (HRPC), to improve response rates and to lower side-effects, as docetaxel-based chemotherapy is an increasing option for men with advanced HRPC, and alone or combined with estramustine, docetaxel improves median survival... CONCLUSIONS: In this randomized phase II study the combination of docetaxel and estramustine had substantial activity in HRPC, with a significant incidence of severe toxicity, both haematological and not. Nevertheless, treatment-related toxicity was predictable and manageable. There was no better effect with a higher dose of estramustine with docetaxel than for a lower dose. There was a slight tendency to higher toxicity for high-dose estramustine but this was not statistically significant. The present results support the assertion that estramustine is not necessary in docetaxel-based treatment regimens.
Clinical Trials Related to Emcyt (Estramustine)
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer [Completed]
we propose to randomize patients with hormone resistant prostate cancer between
docetaxel/estramustine/prednisone and docetaxel/prednisone in a phase II study. The principal
endpoint will be the efficacy in term of PSA response.
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer [Recruiting]
The purpose of this clinical trial is to find out the effect of epirubicin with estramustine
phosphate and celecoxib on PSA and objective response in patients with hormone resistant
prostate cancer as well as evaluating the toxicity, quality of life of this combination.
Celecoxib is an FDA approved drug to treat arthritis. Epirubicin, alone or with
estramustine phosphate has been used in the treatment of hormone resistant prostate cancer.
These drugs have demonstrated evidences of tumor blood vessel suppression and combination
of these three drugs could possibly arrest further tumor growth or even make the tumor
decrease in size.
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy [Active, not recruiting]
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the
tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and estramustine
with thalidomide in treating patients who have prostate cancer previously treated with
hormone therapy.
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer [Active, not recruiting]
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and
Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the
treatment of hormone refractory prostate cancer. The investigators will determine the
tolerable dose of (oral) vinorelbine in combination with (oral)estramustine, and evaluate the
efficacy of this treatment for patients with hormone-refractory prostate cancer.
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate [Active, not recruiting]
Hormonal therapy is the standard treatment for prostate cancer which has spread to other
areas of the body. Despite the high initial response rates to hormonal therapy, the vast
majority of men will develop cancer which is no longer responsive to hormone deprivation. The
average time for hormonal therapy to be effective is about 18 months. Chemotherapy
combinations which can treat the disease when it no longer responds to hormonal therapy have
been developed, but these treatments are not curative. One of these combinations is
estramustine, etoposide and paclitaxel. In men with far advanced disease, 60% will have a
decrease in their PSA or shrinkage of tumors after treatment with this chemotherapy. Despite
this, these men have all developed further disease progression requiring additional
treatment. One possible way to make chemotherapy more effective is to give it when the number
of tumor cells is smallest, and the number of cells to be killed is at a low level. One
situation in which this is true is when a man has responded to hormonal therapy any tumors
are at their smallest size. This study will test whether the addition of chemotherapy at that
time will prolong the time until the cancer becomes unresponsive to hormonal therapy.
|
